Please login to the form below

Not currently logged in
Email:
Password:

ADC Therapeutics expands team

Appointments preceed its first antibody drug conjugate trials

edit-ADC_Therapeutics_Logo_RGBADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

Oncology drug development company's new team members include Jay Feingold joins as CMO and head of oncology clinical development.

He has more than 25 years of industry, academic and medical experience and most recently worked as VP US medical affairs and chairman global medical affairs oversight committee at Daiichi Sankyo.

ADC has also appointed Michael Mulkerrin as head of CMC (chemistry manufacturing and control).

He has more than 20 years of industry experience in biologics manufacturing and recently work as VP process development and manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech.

Additionally, Simon Chivers joins ADC as head of toxicology, Lisa Skelton is appointed as senior project manager for lead programme ADCT-301, Karin Havenith join as senior bioanalytical scientist, Francesca Zammarchi will work as cancer biologist, Dulce Gonclaves will serve as corporate counsel and Stephane Henchoz will be director of finance.

Michael Forer, CEO of ADC Therapeutics, said: “The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs. This expansion underlines the progress we have made since the Company was established in early 2002.”

1st October 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics